Cellular Biomedicine Group, Inc

(NASDAQ:CBMG)

Latest On Cellular Biomedicine Group, Inc (CBMG):

Date/Time Type Description Signal Details
2020-12-13 03:27 ESTFinancialsCompany financials have been released.Neutral
2020-11-15 11:32 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 11:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 09:03 ESTNewsCellular Biomedicine EPS misses by $0.20N/A
2020-11-02 20:51 ESTNewsCellular Biomedicine Group, Inc.: 10% Return In A Few Months As Merger Should Receive ApprovalN/A
2020-11-01 17:27 ESTFinancialsCompany financials have been released.Neutral
2020-09-24 00:24 ESTFinancialsCompany financials have been released.Neutral
2020-09-19 08:27 ESTFinancialsCompany financials have been released.Neutral
2020-09-01 20:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-15 08:19 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 16:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $28 to $19.Neutral
2020-08-13 13:49 ESTNewsCellular Biomedicine EPS beats by $0.04N/A
2020-08-12 11:49 ESTNewsCellular Biomedicine up 37% on go-private dealN/A
2020-07-31 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:32 ESTFinancialsCompany financials have been released.Neutral
2020-07-20 12:21 ESTAnalyst RatingThe Analyst Target Price has increased from $19 to $28.Buy
2020-07-10 08:21 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 08:17 ESTFinancialsCompany financials have been released.Neutral
2020-06-30 23:54 ESTNewsCellular Biomedicine to update on pipeline July 13N/A
2020-06-02 04:22 ESTEarnings EstimateAn EPS average of -$0.68 is estimated for the quarter ending on September 30, 2020.Sell
2020-05-31 16:49 ESTFinancialsCompany financials have been released.Neutral
2020-05-11 13:50 ESTNewsCellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2020 Results - Earnings Call TranscriptN/A
2020-05-08 08:18 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 18:36 ESTNewsCellular Biomedicine EPS beats by $0.16N/A
2020-05-03 08:24 ESTFinancialsCompany financials have been released.Neutral
2020-04-20 04:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $23 to $19.Neutral
2020-04-11 06:36 ESTNewsCellular Biomedicine EPS beats by $0.08N/A
2020-04-11 06:32 ESTNewsBofA raises view on Amgen in premarket analyst actionN/A
2020-04-11 06:06 ESTNewsCellular Biomedicine on go with China study of CAR T for multiple myelomaN/A
2020-04-07 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-03-05 23:17 ESTAnalyst RatingThe Analyst Target Price has decreased from $24 to $23.Neutral
2020-03-02 19:12 ESTNewsCellular Biomedicine Group's (CBMG) CEO Tony Liu on Q4 2019 Results - Earnings Call TranscriptN/A
2020-03-02 03:18 ESTEarnings EstimateAn EPS average of -$2.88 is estimated for the 2021 year.Sell
2020-03-02 03:18 ESTEarnings EstimateAn EPS average of -$0.61 is estimated for the quarter ending on June 30, 2020.Buy
2020-02-29 23:22 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 23:20 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 03:22 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 03:22 ESTEarningsEarnings have been released on March 6, 2018, with -$0.48 earnings per share.Neutral
2020-02-21 23:16 ESTFinancialsCompany financials have been released.Neutral
2020-02-06 23:18 ESTFinancialsCompany financials have been released.Neutral
2020-01-29 23:19 ESTFinancialsCompany financials have been released.Neutral
2020-01-28 03:23 ESTEarningsEarnings have been released on May 9, 2017, with -$0.43 earnings per share.Sell
2020-01-27 23:16 ESTFinancialsCompany financials have been released.Neutral
2020-01-21 19:17 ESTEarningsEarnings have been released on November 6, 2019, with -$0.82 earnings per share.Sell
2020-01-15 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-12-16 23:18 ESTFinancialsCompany financials have been released.Neutral
2019-12-11 09:02 ESTNewsCellular Biomedicine Group (CBMG) Presents At 2019 ASH Annual Meeting - SlideshowN/A
2019-11-27 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-11-26 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-11-22 23:15 ESTFinancialsCompany financials have been released.Neutral

About Cellular Biomedicine Group, Inc (CBMG):

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

CBMG Quotes by TradingView

See Advanced Chart

General

  • Name Cellular Biomedicine Group, Inc
  • Symbol CBMG
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 217
  • Last Split Factor1:100
  • Last Split Date2013-01-31
  • Fiscal Year EndDecember
  • IPO Date2014-03-21
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.cellbiomedgroup.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1184.26
  • Price/Book (Most Recent Quarter) 22.21
  • Enterprise Value Revenue 1258.81
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Operating Margin -17044%
  • Return on Assets -35%
  • Return on Equity -130%
  • Revenue 322950
  • Earnings Per Share -$2.32
  • Revenue Per Share $0.02
  • Gross Profit 277542
  • Quarterly Earnings Growth 1031%
View More

Highlights

  • Market Capitalization 384.69 million
  • EBITDA -36203524
  • Analyst Target Price $19
  • Book Value Per Share $0.89
View More

Share Statistics

  • Shares Outstanding 19.48 million
  • Shares Float 15.23 million
  • % Held by Insiders 4470%
  • % Held by Institutions 33.84%
  • Shares Short 290041
  • Shares Short Prior Month 284052
  • Short Ratio 3.48
  • Short % of Float 3%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.21
  • 52 Week High $19.76
  • 52 Week Low $11.9
  • 50 Day Moving Average 18.91
  • 200 Day Moving Average 18.44
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cellular Biomedicine Group, Inc (CBMG) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cellular Biomedicine Group, Inc (CBMG) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-09$N/A-$0.88-$0.68-29.41%
2020-06-302020-08-12$N/A-$0.70-$0.745.41%
2020-03-312020-05-06$N/A-$0.60-$0.7621.05%
2019-12-312020-02-28$290655-$0.66-$0.7410.81%
2019-09-302019-11-06$N/A-$0.82-$0.67-22.85%
2019-06-302019-08-06$N/A-$0.63-$0.52-20.39%
2019-03-312019-04-30$49265-$0.51-$0.6015%
2018-12-312019-02-19$25698-$0.45-$0.37-21.62%
2018-09-302018-11-06$70431-$0.72-$0.52-38.46%
2018-06-302018-08-07$77313-$0.53-$0.52-1.92%
2018-03-312018-05-07$50961-$0.51-$0.47-8.51%
2017-12-312018-03-05$69000-$0.48-$0.480%
2017-09-302017-11-08$107000-$0.43-$0.4810.42%
2017-06-302017-08-08$63000-$0.43-$0.466.52%
2017-03-312017-05-08$98000-$0.43-$0.43-0.35%
2016-12-312017-03-13$58000-$0.42-$0.432.33%
2016-09-302016-11-08$10000-$0.75
2016-06-302016-08-09$72000-$0.52
2016-03-312016-05-09$488000-$0.35
2015-12-312016-03-14$620000-$0.43-$0.42-2.38%
2015-09-302015-11-13$625000-$0.44-$0.43-2.33%
2015-06-302015-08-14$657000-$0.44-$0.37-18.92%
2015-03-312015-05-18$603000-$0.39-$0.402.5%
2014-12-312015-03-31$-1251489-$0.57-$0.32-78.13%
2014-09-302014-11-19$-118000-$0.31
2014-06-302014-06-30$118000-$0.85
2014-03-312014-03-31$1.7 million-$0.06
2013-12-312013-12-31$564802-$0.87
2013-09-302013-09-30$3.19 million$0.09
2013-06-302013-06-30$111434-$0.44
2013-03-312013-03-31$N/A-$1.25
2012-12-312012-12-31$3.35 million$285.87
2012-09-302012-09-30$5.89 million$3.30
2012-06-302012-06-30$166771-$0.11
2012-03-312012-03-31$79000-$0.16
2011-12-312011-12-31-$0.01
2011-09-302011-09-30$3000-$0.05
2011-06-302011-06-30$28000-$0.23
2011-03-312011-03-31-$0.22
2010-12-312010-12-31$0.94
2010-09-302010-09-30-$0.13
2010-06-302010-06-30-$0.25
2010-03-312010-03-31-$0.70
2009-12-312009-12-31-$0.17
2009-09-302009-09-30-$0.10
2009-06-302009-06-30-$0.16
2009-03-312009-03-31-$0.16
2008-12-312008-12-31-$0.54
2008-09-302008-09-30-$0.09
2008-06-302008-06-30-$0.14
2008-03-312008-03-31-$0.11

Cellular Biomedicine Group, Inc (CBMG) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A 10.09 million N/A 9.51 million 13.13 million
Income Before Tax N/A -13.53 million N/A -12.69 million -15.86 million
Selling General Administrative N/A 3.28 million N/A 3.52 million 3.36 million
Gross Profit N/A N/A N/A 236364 N/A
Ebit N/A -11.8 million N/A -12.8 million -16.49 million
Operating Income N/A -13.37 million N/A -12.8 million -16.49 million
Income Tax Expense N/A N/A 1775 -2380 -325
Total Revenue N/A N/A N/A 290655 N/A
Cost of Revenue N/A N/A N/A 54291 N/A
Total Other Income Expense Net N/A -188153 N/A 110146 627365
Net Income From Continuing Operations N/A -13.53 million N/A -12.69 million -15.86 million
Net Income Applicable to Common Shares -17.04 million -13.53 million -11.55 million -12.69 million -15.86 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A -2.99 million N/A N/A N/A
Change to Liabilities 1.23 million 534563 -744090 -3.52 million 4.36 million
Total Cash Flow from Investing Activities -2.61 million -2.99 million -1.63 million -2.12 million -1.06 million
Net Borrowings 28.4 million 5.46 million -315898 N/A N/A
Total Cash Flow from Financial Activities N/A 5.46 million N/A -73263 -119308
Change to Operating Activities -97118 41082 223710 2.08 million -381865
Change in Cash N/A -8.02 million N/A -13.59 million -10.68 million
Total Cash from Operating Activities -13.35 million -10.52 million -9.29 million -11.6 million -9.4 million
Depreciation N/A 1.56 million N/A 1.54 million 1.44 million
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A 11 -22
Other Cash Flow from Financing Activities N/A N/A N/A -161491 -164251
Change to Net Income 891011 868927 1.18 million 994006 1.04 million
Capital Expenditures N/A N/A N/A 2.03 million 1.18 million
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A 45.04 million N/A 41.61 million 38.4 million
Total Stockholder Equity N/A 32.53 million N/A 55.72 million 67.05 million
Other Current Liabilities 6.95 million 5.72 million N/A 5.39 million 2.54 million
Total Assets N/A 77.57 million N/A 97.32 million 105.45 million
Common Stock 20506 20482 20427 20360 20328
Other Current Assets N/A N/A N/A 17 million 17 million
Retained Earnings -242.08 million -225.05 million -211.51 million -199.97 million -187.28 million
Other Liabilities 16.47 million 238435 17.2 million 17.93 million 262977
Other Assets 7.88 million 7.05 million 7 million 6.46 million 7.64 million
Cash N/A 13.58 million N/A 15.44 million 29.04 million
Total Current Liabilities 59.3 million 28.45 million N/A 23.67 million 25.86 million
Other Stockholder Equity -958985 -1.85 million -1.9 million -1.46 million -1.77 million
Property, Plant & Equipment 43.21 million 41.11 million 40.62 million 41.54 million 34.15 million
Total Current Assets 27.87 million 14.98 million N/A 34.03 million 48.22 million
Long Term Investments N/A N/A N/A 240000 240000
Net Tangible Assets 3.2 million 18.11 million 30.44 million 40.66 million 51.85 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 2.75 million 1.52 million N/A 2.04 million 5.69 million

Cellular Biomedicine Group, Inc (CBMG) Chart:

Cellular Biomedicine Group, Inc (CBMG) News:

Below you will find a list of latest news for Cellular Biomedicine Group, Inc (CBMG) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cellular Biomedicine Group, Inc (CBMG) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Cellular Biomedicine Group, Inc (CBMG) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420007052/0001654954-20-007052-index.htm
2018-10-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1378624/000000000018032859/0000000000-18-032859-index.htm
2019-05-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1378624/000000000019008739/0000000000-19-008739-index.htm
2019-06-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1378624/000000000019010257/0000000000-19-010257-index.htm
2019-07-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1378624/000000000019010750/0000000000-19-010750-index.htm
2019-07-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1378624/000000000019011113/0000000000-19-011113-index.htm
2019-11-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266419004261/0000902664-19-004261-index.htm
2019-11-13SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266419004285/0000902664-19-004285-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266419004381/0000902664-19-004381-index.htm
2019-11-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266419004398/0000902664-19-004398-index.htm
2019-11-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266419004399/0000902664-19-004399-index.htm
2019-11-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266419004400/0000902664-19-004400-index.htm
2020-01-30SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420000597/0000902664-20-000597-index.htm
2020-01-30SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420000598/0000902664-20-000598-index.htm
2020-02-03SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420000642/0000902664-20-000642-index.htm
2020-02-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266420000664/0000902664-20-000664-index.htm
2020-02-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001296/0000902664-20-001296-index.htm
2020-02-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001297/0000902664-20-001297-index.htm
2020-02-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001298/0000902664-20-001298-index.htm
2020-02-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001299/0000902664-20-001299-index.htm
2020-02-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001368/0000902664-20-001368-index.htm
2020-02-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001369/0000902664-20-001369-index.htm
2020-02-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001370/0000902664-20-001370-index.htm
2020-02-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001371/0000902664-20-001371-index.htm
2020-02-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001372/0000902664-20-001372-index.htm
2020-03-30SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001666/0000902664-20-001666-index.htm
2020-04-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001688/0000902664-20-001688-index.htm
2020-04-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001689/0000902664-20-001689-index.htm
2020-04-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420001690/0000902664-20-001690-index.htm
2020-06-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420002501/0000902664-20-002501-index.htm
2020-06-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420002502/0000902664-20-002502-index.htm
2020-08-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000090266420002963/0000902664-20-002963-index.htm
2020-08-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000110465920095581/0001104659-20-095581-index.htm
2020-08-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000110465920095585/0001104659-20-095585-index.htm
2018-09-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1378624/000112329218000974/0001123292-18-000974-index.htm
2019-11-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000118518519001621/0001185185-19-001621-index.htm
2020-02-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000118518520000116/0001185185-20-000116-index.htm
2020-02-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000118518520000202/0001185185-20-000202-index.htm
2020-03-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000118518520000400/0001185185-20-000400-index.htm
2020-06-25SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000118518520000892/0001185185-20-000892-index.htm
2020-08-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000118518520001132/0001185185-20-001132-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000119312520216973/0001193125-20-216973-index.htm
2020-08-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1378624/000119312520216977/0001193125-20-216977-index.htm
2020-08-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1378624/000119312520216988/0001193125-20-216988-index.htm
2020-10-09PREM14APreliminary proxy statements relating to merger or acquisitionhttps://www.sec.gov/Archives/edgar/data/1378624/000119312520266721/0001193125-20-266721-index.htm
2020-10-09SC 13E3Going private transaction by certain issuershttps://www.sec.gov/Archives/edgar/data/1378624/000119312520266748/0001193125-20-266748-index.htm
2018-04-11424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1378624/000165495418003815/0001654954-18-003815-index.htm
2018-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495418003882/0001654954-18-003882-index.htm
2018-04-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418004095/0001654954-18-004095-index.htm
2018-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418004234/0001654954-18-004234-index.htm
2018-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418004477/0001654954-18-004477-index.htm
2018-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1378624/000165495418004805/0001654954-18-004805-index.htm
2018-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495418005772/0001654954-18-005772-index.htm
2018-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495418005773/0001654954-18-005773-index.htm
2018-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495418005774/0001654954-18-005774-index.htm
2018-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495418005775/0001654954-18-005775-index.htm
2018-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495418005776/0001654954-18-005776-index.htm
2018-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495418005777/0001654954-18-005777-index.htm
2018-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418006856/0001654954-18-006856-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1378624/000165495418008569/0001654954-18-008569-index.htm
2018-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418010529/0001654954-18-010529-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418010733/0001654954-18-010733-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418010930/0001654954-18-010930-index.htm
2018-10-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418010934/0001654954-18-010934-index.htm
2018-10-10S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1378624/000165495418010954/0001654954-18-010954-index.htm
2018-10-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1378624/000165495418011402/0001654954-18-011402-index.htm
2018-10-23424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1378624/000165495418011466/0001654954-18-011466-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418011643/0001654954-18-011643-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1378624/000165495418012031/0001654954-18-012031-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418012131/0001654954-18-012131-index.htm
2018-12-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1378624/000165495418013758/0001654954-18-013758-index.htm
2018-12-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495418014357/0001654954-18-014357-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419000126/0001654954-19-000126-index.htm
2019-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419000251/0001654954-19-000251-index.htm
2019-01-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419000542/0001654954-19-000542-index.htm
2019-01-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419000788/0001654954-19-000788-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495419001593/0001654954-19-001593-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495419001595/0001654954-19-001595-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495419001597/0001654954-19-001597-index.htm
2019-02-1910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1378624/000165495419001756/0001654954-19-001756-index.htm
2019-03-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419002157/0001654954-19-002157-index.htm
2019-03-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1378624/000165495419002827/0001654954-19-002827-index.htm
2019-03-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1378624/000165495419002829/0001654954-19-002829-index.htm
2019-03-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1378624/000165495419002988/0001654954-19-002988-index.htm
2019-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419002990/0001654954-19-002990-index.htm
2019-03-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419003100/0001654954-19-003100-index.htm
2019-03-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1378624/000165495419003104/0001654954-19-003104-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419003515/0001654954-19-003515-index.htm
2019-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419004670/0001654954-19-004670-index.htm
2019-04-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419004765/0001654954-19-004765-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419004939/0001654954-19-004939-index.htm
2019-04-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1378624/000165495419005054/0001654954-19-005054-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419006213/0001654954-19-006213-index.htm
2019-06-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1378624/000165495419007001/0001654954-19-007001-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419007375/0001654954-19-007375-index.htm
2019-06-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1378624/000165495419007735/0001654954-19-007735-index.htm
2019-07-01S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1378624/000165495419007858/0001654954-19-007858-index.htm
2019-07-03424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1378624/000165495419007957/0001654954-19-007957-index.htm
2019-07-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1378624/000165495419007998/0001654954-19-007998-index.htm
2019-07-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1378624/000165495419008243/0001654954-19-008243-index.htm
2019-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419008411/0001654954-19-008411-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1378624/000165495419008900/0001654954-19-008900-index.htm
2019-08-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419010134/0001654954-19-010134-index.htm
2019-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419010582/0001654954-19-010582-index.htm
2019-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419010612/0001654954-19-010612-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419011185/0001654954-19-011185-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419011398/0001654954-19-011398-index.htm
2019-10-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495419011771/0001654954-19-011771-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495419011772/0001654954-19-011772-index.htm
2019-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419011839/0001654954-19-011839-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1378624/000165495419012421/0001654954-19-012421-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419012516/0001654954-19-012516-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419012639/0001654954-19-012639-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419012712/0001654954-19-012712-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419013694/0001654954-19-013694-index.htm
2019-12-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495419014282/0001654954-19-014282-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420000898/0001654954-20-000898-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420001535/0001654954-20-001535-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420001538/0001654954-20-001538-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420001540/0001654954-20-001540-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420001851/0001654954-20-001851-index.htm
2020-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1378624/000165495420002065/0001654954-20-002065-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420003781/0001654954-20-003781-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420004551/0001654954-20-004551-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420004552/0001654954-20-004552-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420004553/0001654954-20-004553-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420004554/0001654954-20-004554-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420004555/0001654954-20-004555-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420004556/0001654954-20-004556-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420004651/0001654954-20-004651-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1378624/000165495420004652/0001654954-20-004652-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1378624/000165495420004977/0001654954-20-004977-index.htm
2020-05-08DEFR14ARevised definitive proxy soliciting materialshttps://www.sec.gov/Archives/edgar/data/1378624/000165495420005070/0001654954-20-005070-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420006859/0001654954-20-006859-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420007052/0001654954-20-007052-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420007599/0001654954-20-007599-index.htm
2020-08-10NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/1378624/000165495420008719/0001654954-20-008719-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1378624/000165495420008950/0001654954-20-008950-index.htm
2020-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420009589/0001654954-20-009589-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1378624/000165495420011426/0001654954-20-011426-index.htm
2018-04-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1378624/999999999518000787/9999999995-18-000787-index.htm
2018-10-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1378624/999999999518002680/9999999995-18-002680-index.htm
2019-07-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1378624/999999999519001620/9999999995-19-001620-index.htm
2018-10-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1378624/999999999718008679/9999999997-18-008679-index.htm
2018-10-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1378624/999999999718008681/9999999997-18-008681-index.htm
2019-03-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1378624/999999999719001303/9999999997-19-001303-index.htm
2019-03-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1378624/999999999719001460/9999999997-19-001460-index.htm
2019-09-26CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1378624/999999999719007130/9999999997-19-007130-index.htm

Cellular Biomedicine Group, Inc (CBMG) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cellular Biomedicine Group, Inc (CBMG). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4470%
Institutional Ownership: 3384%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-04-10Wen Tao LiuDirectorSell10,400.0020.10208,988.00213,076.00https://www.sec.gov/Archives/edgar/data/1378624/000165495418003882/0001654954-18-003882-index.htm
2018-04-11Wen Tao LiuDirectorSell12,044.0020.08241,843.52213,076.00https://www.sec.gov/Archives/edgar/data/1378624/000165495418003882/0001654954-18-003882-index.htm
2018-04-10Wen Tao LiuDirectorBuy10,400.0015.53161,512.00223,476.00https://www.sec.gov/Archives/edgar/data/1378624/000165495418003882/0001654954-18-003882-index.htm
2018-04-11Wen Tao LiuDirectorBuy12,044.0015.53187,043.32225,120.00https://www.sec.gov/Archives/edgar/data/1378624/000165495418003882/0001654954-18-003882-index.htm